The objective of this study was to reveal the adjuvant's effect of different adjuvants on the immune response of trivalent Foot and mouth disease (FMD) vaccine in cattle.
MATERIALS AND METHODS

Animals (Cattle)
Twenty seven calves, native breed, between 6 to 9 months old and weighted between 300 and 400 kg, twenty calves were divided into four groups, each of five animals, one group vaccinated intramuscularly (I/M) with trivalent FMD ISA 206 oil vaccine, second group vaccinated intramuscularly (I/M) with trivalent FMD ISA 206-aluminum hydroxide gel vaccine, third group vaccinated intramuscularly (I/M) with trivalent ISA 201 oil vaccine,, fourth group vaccinated intramuscularly (I/M) with trivalent ISA 201-aluminum hydroxide gel vaccine, three cattle were used as negative control (non-vaccinated) and four cattle were used for safety test.
FMD virus Strains
FMD virus local strains (O /pan Asia2, A/ Iran 05, SAT2/ Egypt 2012 and SAT2/ Egypt 2018) were locally isolated and were identified by Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo. These viruses were used in vaccine preparation and serum neutralization test (SNT).
Adjuvants
A-ISA206: Montanide ISA 206 was obtained from Seppic, Paris, France.
B-ISA201:
Montanide ISA 201 was obtained from Seppic, Paris, France.
C-Aluminium Hydroxide Gel: 2.5% aluminum hydroxide gel was prepared as an alum-based adjuvant.
FMD Polyvalent Vaccine
Local strains of FMD were propagated in baby hamster kidney cells-clone 21 (BHK-21) cell line and inactivated by Binary Ethylenemine (BEI).
A. Preparation of the ISA 206 Adjuvant Vaccine
Inactivated ISA 206 oil adjuvanated FMD Vaccines were formulated according to Barnett.et.al. (1996) . The ratio of the aqueous antigen to the oil adjuvant was 50:50 (w/w) according to OIE (2000).
B. Preparation of the ISA206 -Aluminium Hydroxide Gel Adjuvant Vaccine
Inactivated ISA 206 oil adjuvanated FMD Vaccines were formulated according to Barnett.et.al. (1996) . The ratio of the aqueous antigen to the oil adjuvant was 50:50 (w/w) according to OIE (2000). Aluminium hydroxide gel was added as 30% of the aqueous phase of the vaccine bulk. 
C. Preparation of the ISA201 Adjuvant Vaccines
Safety of the Prepared Vaccines
Safety test for the formulated FMD vaccines:
The inactivated FMD virus was tested for safety in vitro on BHK-21 cell line and the whole prepared vaccines in vivo in susceptible cattle OIE (2000).
Safety of the prepared vaccines were done according to Code of Federal regulation of USA.
(1986), Henderson (1970) and OIE (2000).
EXPERIMENTAL DESIGN
Twenty seven calves, native breed, between 6 to 9 months old and weighted between 300 and 400 kg, twenty calves were divided into four groups, each of five animals, one group vaccinated intramuscularly (I/M) with trivalent FMD ISA 206 oil vaccine, second group vaccinated intramuscularly (I/M) with trivalent FMD ISA 206-aluminum hydroxide gel vaccine, third group vaccinated intramuscularly (I/M) with trivalent ISA 201 oil vaccine,, fourth group vaccinated intramuscularly (I/M) with trivalent ISA 201-aluminum hydroxide gel vaccine, three cattle were used as negative control (non-vaccinated) and four cattle were used for safety test. Serum samples were collected from vaccinated animals for 10 months.
Heparinized blood samples were obtained from vaccinated and control non vaccinated animals at 0, 3, 7, 14, 21,28,35 and 42 days post vaccination. Stimulation of the cellular immune response by the different prepared FMD vaccine was evaluated by Lymphocyte blastogenesis using cell proliferation kit (XTT kit).
Serum samples were collected weekly post vaccination for one month then every month post-vaccination till the end of experiment (ten months). The immune response was evaluated through SNT test.
RESULTS AND DISCUSSION
Foot and Mouth Disease (FMD) is an acute disease caused by Foot and Mouth Disease Virus (FMDV) which causes important economy losses (Orsel et al., 2007).
The control of FMD in animals was considered to be important to effectively contain the disease in endemic areas, so that vaccination of animals is effective in limiting the spread of FMD.
FMD vaccines can be defined as a fixed formulation of that of specific amount of chemically inactivated virus strains and mixing with suitable adjuvant. Selecting the suitable vaccine formulation is dependent on several factors as the onset of protection and the duration of protection against FMD.
The effective formulation of inactivated FMD vaccines requires adjuvant aluminium hydroxide gel and mineral oils-based formulations have been widely employed in experimental studies to obtain a vaccine that stimulates a rapid and long-lasting protective immune response, the formulated vaccines are safe for animal use.
Results in table (1) showed that the five prepared vaccines were safe for use during the whole experiment time. These results were in agreement with (OIE 2000). ISA201  ISA201＋AL*  ISA206  ISA206＋AL*  1  safe  safe  safe  safe  2  safe  safe  safe  safe  3  safe  safe  safe  safe  4  safe  safe  safe  safe  5  safe  safe  safe  safe  6  safe  safe  safe  safe  7  safe  safe  safe  safe  8  safe  safe  safe  safe  9  safe  safe  safe  safe  10 safe safe safe safe AL * aluminium hydroxide gel
Table1. Safety of polyvalent FMD vaccines tested
Months post vaccination
Polyvalent FMD Vaccines
The obtained results of cell mediated immune response using lymphocyte proliferation test for all animal groups expressed by ΔOD (Delta Optical Density) were as follow: The SNT data in tables 6,7,8 and 9 showed the differences in the onset, intensity and duration of the antibodies elicited by the different vaccine formulations against FMD virus serotypes O, A, SAT2/2012 and SAT2/2018. Results showed that vaccines prepared with ISA 206 and ISA 206＋aluminum hydroxide gel induce better humeral immunity than that induced by vaccines prepared with ISA 201 and ISA 201＋aluminum hydroxide gel, the results obtained are consistent with the statement of Wisniewski et al., (1972) they explained that the SNT measures those antibodies which neutralize the infectivity of FMD virion. The peak of antibody titre in all groups at 10-12 weeks post vaccination and continues with protective level till 32 th week post vaccination. Our results also were consistent with the statement of (Hamblin et al., (1986) who explained that the SNT measures those antibodies which neutralize the infectivity of FMD virion, while ELISA probably measure all classes of antibodies even those produced against incomplete and non-infectious virus. , (2002 a,b) . The combined components of oil and aluminium hydroxide gel have been used to protect against rabies in bovines Reddy and Srinivasan (1996) .
Table6. Mean of serum antibody titers in cattle vaccinated with polyvalent FMD ISA 206 oil vaccine using SNT expressed log 10
Weeks post vaccination
Mean antibody titer against FMD virus strains Non vaccinated Group FMD (O) FMD (A) FMD (SAT/2012) FMD (SAT/2018)
Weeks post vaccination
Mean antibody titer against FMD virus strains Non vaccinated Group FMD (O) FMD (A) FMD (SAT/2012) FMD (SAT/2018)
Weeks post vaccination
Mean antibody titer against FMD virus strains Non vaccinated Group FMD (O) FMD (A) FMD (SAT/2012) FMD (SAT/2018)
In this study, we tested a combination of oil with aluminium hydroxide gel to enhance the immune responses. We found that vaccines prepared with ISA 201 and ISA 201＋aluminum hydroxide gel induced better cellular immunity than that induced by vaccines prepared with ISA 206 and ISA 2016＋aluminum hydroxide gel, also found that vaccines prepared with ISA 206 and ISA 206＋aluminum hydroxide gel induce better humeral immunity than that induced by vaccines prepared with ISA 201 and ISA 201＋aluminum hydroxide gel. We concluded that aluminum hydroxide gel improves the effects of ISA adjuvants.
In the present study, we thus attempted to demonstrate that mixing of various oiladjuvants and aluminium hydroxide gel would induces similar protection in cattle. We confirmed slight increases in the level of cellular and humeral immune response after using aluminium hydroxide gel.
Finally, Oil-adjuvanated vaccines can result in the formation of local lesions in the injected areas. Thus, to avoid granuloma, long-term studies with a reduced volume of vaccines should be carried out to identify whether such lesions increase or decrease when aluminum hydroxide gel is added to the vaccines. In addition, comparative studies on long-lasting immunity in experimental and target animals may be required for the development of new vaccines.
